

Resource Summary Report

Generated by PRECISE-TBI on Sep 8, 2026

Edelris

RRID:SCR_004112

Type: Tool

Proper Citation

Edelris (RRID:SCR_004112)

Resource Information

URL: <http://www.edelris.com/>

Proper Citation: Edelris (RRID:SCR_004112)

Description: A commercial medicinal chemistry company dedicated to the design and synthesis of natural product-mimetic screening compounds, Hit-to-Lead & Lead Optimization projects and Custom Synthesis. Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELIRIS uses its validated chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit-to-lead optimization capabilities. EDELIRIS has a wide range of services and based on its experience in various and complementary fields, the team is capable to deliver innovative solutions to synthetic and medicinal chemistry problems faced by clients.

Abbreviations: Edelris

Resource Type: commercial organization

Keywords: screening compound, chemical, small molecule, drug discovery, natural product

Resource Name: Edelris

Resource ID: SCR_004112

Alternate IDs: nlx_158590

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260905T132515+0000

Ratings and Alerts

No rating or validation information has been found for Edelris.

No alerts have been found for Edelris.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Bosc L, et al. (2025) Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound. Science advances, 11(44), eadw6328.

Mullapudi ST, et al. (2018) Screening for insulin-independent pathways that modulate glucose homeostasis identifies androgen receptor antagonists. eLife, 7.